- Report
- May 2020
- 185 Pages
Global
From €3692EUR$4,150USD£3,188GBP
- Report
- August 2024
- 200 Pages
Global
From €2215EUR$2,490USD£1,913GBP
- Report
- January 2024
- 150 Pages
Global
From €3425EUR$3,850USD£2,958GBP
€4315EUR$4,850USD£3,726GBP
- Report
- November 2021
- 101 Pages
Global
From €4004EUR$4,500USD£3,457GBP
- Report
- May 2024
- 133 Pages
Global
From €5782EUR$6,499USD£4,993GBP
- Report
- January 2022
- 60 Pages
Global
From €3514EUR$3,950USD£3,035GBP
- Report
- January 2022
- 60 Pages
Global
From €3514EUR$3,950USD£3,035GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4404EUR$4,950USD£3,803GBP
- Report
- April 2023
- 115 Pages
Global
From €4226EUR$4,750USD£3,649GBP
- Report
- April 2023
- 117 Pages
Global
From €4226EUR$4,750USD£3,649GBP
- Report
- March 2023
- 147 Pages
Global
From €4403EUR$4,949USD£3,802GBP
- Clinical Trials
- December 2023
- 2092 Pages
Global
From €2224EUR$2,500USD£1,921GBP
- Report
- January 2023
- 90 Pages
Global
From €3109EUR$3,495USD£2,685GBP
- Report
- August 2022
- 541 Pages
Global
From €2224EUR$2,500USD£1,921GBP
- Report
- July 2022
- 518 Pages
Global
From €1779EUR$2,000USD£1,536GBP
- Report
- May 2023
- 79 Pages
Global
From €3500EUR$4,214USD£3,128GBP
- Report
- May 2023
- 109 Pages
Global
From €3500EUR$4,214USD£3,128GBP
- Report
- January 2025
- 132 Pages
Global
From €845EUR$950USD£730GBP
- Report
- January 2025
- 132 Pages
Global
From €845EUR$950USD£730GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more